Novartis (NVS)
(Delayed Data from NYSE)
$105.33 USD
-0.80 (-0.75%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $105.32 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth F Momentum C VGM
Revenue - Line of Business Segments | YR Estimate | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|---|
Revenues: Established Brands: Afi... |
-- | 512 | 417 | 417 | 1,083 | 1,539 |
Revenues: Hematology: Promacta/Re... |
-- | 2,269 | 2,088 | 2,016 | 1,738 | 1,416 |
Revenues: Other Promoted Brands: ... |
-- | -- | 479 | 584 | 623 | 630 |
Revenues: Established Brands: Gal... |
-- | 692 | 859 | 1,092 | 1,199 | 1,297 |
Revenues: Established Brands: Exf... |
-- | 713 | 743 | 901 | 980 | 1,025 |
Revenues: Hematology: Kymriah - T... |
-- | 508 | 536 | 587 | 474 | 278 |
Revenues: Hematology: Tasigna - T... |
-- | 1,848 | 1,923 | 2,060 | 1,958 | 1,880 |
Revenues: Other Promoted Brands: ... |
-- | 1,475 | 1,874 | 2,160 | 1,933 | 2,086 |
Revenues: Established Brands: Gle... |
-- | 561 | 745 | 1,024 | 1,188 | 1,263 |
Revenues: Established Brands: San... |
-- | 1,314 | 1,238 | 1,413 | 1,439 | 1,585 |
Revenues: Hematology: Jakavi - To... |
-- | 1,720 | 1,561 | 1,595 | 1,339 | 1,114 |
Revenues: Established Brands: Dio... |
-- | 613 | 652 | 773 | 1,003 | 1,064 |
Total Neuroscience [$M] |
-- | 4,043 | 3,038 | 5,007 | -- | -- |
Neuroscience: Mayzent [$M] |
-- | 392 | 357 | 281 | -- | -- |
Solid Tumors: Lutathera [$M] |
-- | 605 | 471 | 475 | -- | -- |
Solid Tumors: Piqray [$M] |
-- | 505 | 373 | 329 | -- | -- |
Solid Tumors: Pluvicto [$M] |
-- | 980 | 271 | -- | -- | -- |
Solid Tumors: Tabrecta [$M] |
-- | 154 | 133 | 90 | -- | -- |
Other Promoted Brands: Beovu [$M] |
-- | -- | 203 | 186 | -- | -- |
Neuroscience: Zolgensma [$M] |
-- | 1,214 | 1,370 | 1,351 | -- | -- |
Hematology: Adakveo [$M] |
-- | 195 | 194 | 164 | -- | -- |
Hematology: Scemblix [$M] |
-- | 413 | 149 | 7 | -- | -- |
Neuroscience: Aimovig [$M] |
-- | 266 | 218 | 215 | -- | -- |
Cardiovascular: Leqvio [$M] |
-- | 355 | 112 | 12 | -- | -- |
Total Immunology [$M] |
-- | 7,798 | 7,287 | 7,205 | -- | -- |
Total Cardiovascular [$M] |
-- | 6,391 | 4,756 | 3,560 | -- | -- |
Other Promoted Brands: Other resp... |
-- | -- | 84 | 53 | -- | -- |
Total Promoted Brands [$M] |
-- | 31,822 | 26,257 | 29,754 | -- | -- |
Established Brands: Contract manu... |
-- | 1,490 | 1,200 | 108 | -- | -- |
Established Brands: Other [$M] |
-- | 5,427 | 6,113 | 4,257 | -- | -- |
Total Established Brand [$M] |
-- | 13,618 | 15,949 | 12,241 | -- | -- |
Neuroscience: Kesimpta [$M] |
-- | 2,171 | 1,092 | 372 | -- | -- |
Revenues: Net sales to third part... |
-- | 45,440 | 42,206 | 51,626 | 48,659 | 47,445 |
Revenues: Other revenues [$M] |
-- | 1,220 | 1,255 | 1,251 | 1,239 | 1,179 |
Revenues: Cardiovascular: Entrest... |
-- | 6,035 | 4,644 | 1,836 | 2,497 | 1,726 |
Revenues: Immunology:Cosentyx - T... |
-- | 4,980 | 4,788 | 3,548 | 3,995 | 3,551 |
Revenues: Immunology: Xolair - To... |
-- | 1,463 | 1,365 | 1,428 | 1,251 | 1,173 |
Revenues: Immunology: Ilaris - To... |
-- | 1,355 | 1,133 | 1,059 | 873 | 671 |
Revenues: Neuroscience: Gilenya -... |
-- | 925 | 2,013 | 2,787 | 3,003 | 3,223 |
Revenues: Solid Tumors: Tafinlar ... |
-- | 1,922 | 1,770 | 1,693 | 1,542 | 1,338 |
Revenues: Solid Tumors: Kisqali -... |
-- | 2,080 | 1,231 | 937 | 687 | 480 |
Revenues: Solid Tumors: Votrient ... |
-- | 390 | 474 | 577 | 635 | 755 |
Revenue - Geographic Segments | YR Estimate | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
Revenues: Hematology: Promacta/Re... |
-- | 1,205 | 1,083 | 947 | 833 | 691 |
Revenues: Immunology: Cosentyx - ... |
-- | 2,636 | 2,770 | 2,883 | 2,516 | 2,220 |
Revenues: Immunology: Cosentyx - ... |
-- | 2,344 | 2,018 | 4,718 | 1,479 | 1,331 |
Revenues: Established Brands: Exf... |
-- | 700 | 729 | 887 | 964 | 1,012 |
Revenues: Established Brands: Gle... |
-- | 150 | 205 | 263 | 315 | 334 |
Revenues: Established Brands: Gle... |
-- | 411 | 540 | 761 | 873 | 929 |
Revenues: Established Brands: San... |
-- | 829 | 800 | 843 | 837 | 881 |
Revenues: Established Brands: San... |
-- | 485 | 438 | 570 | 602 | 704 |
Revenues: Immunology: Ilaris - US... |
-- | 686 | 570 | 501 | 400 | 304 |
Revenues: Immunology: Ilaris - Re... |
-- | 669 | 563 | 558 | 473 | 367 |
Revenues: Established Brands: Dio... |
-- | 52 | 55 | 51 | 124 | 86 |
Revenues: Established Brands: Dio... |
-- | 561 | 597 | 722 | 879 | 978 |
Revenues: Solid Tumors: Kisqali -... |
-- | 1,032 | 472 | 339 | 318 | 250 |
Revenues: Solid Tumors: Kisqali -... |
-- | 1,048 | 759 | 598 | 369 | 230 |
Neuroscience: Zolgensma - US [$M] |
-- | 372 | 434 | 469 | -- | -- |
Neuroscience: Zolgensma - ROW [$M... |
-- | 842 | 936 | 882 | -- | -- |
Revenues: Cardiovascular: Entrest... |
-- | 3,067 | 2,354 | 1,712 | 1,277 | 925 |
Revenues: Cardiovascular: Entrest... |
-- | 2,968 | 2,290 | 1,836 | 1,220 | 801 |
Revenues: Neuroscience: Gilenya -... |
-- | 359 | 1,153 | 1,427 | 1,562 | 1,736 |
Revenues: Neuroscience: Gilenya -... |
-- | 566 | 860 | 1,360 | 1,441 | 1,487 |
Revenues: Hematology: Tasigna - U... |
-- | 884 | 877 | 882 | 859 | 804 |
Revenues: Hematology: Tasigna - R... |
-- | 964 | 1,046 | 1,178 | 1,099 | 1,076 |
Revenues: Solid Tumors: Tafinlar ... |
-- | 791 | 678 | 606 | 569 | 481 |
Revenues: Solid Tumors: Tafinlar ... |
-- | 1,131 | 1,092 | 1,087 | 973 | 857 |
Revenues: Established Brands: Exf... |
-- | 13 | 14 | 14 | 16 | 13 |
Revenues: Hematology: Promacta/Re... |
-- | 1,064 | 1,005 | 1,069 | 905 | 725 |